Group One Trading
BTAI icon

Group One Trading’s BioXcel Therapeutics BTAI Stock Holding History

Group One Trading’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,100
Closed -$6.56K – 7692
2025
Q4 		$6.56K Hold
4,100
– – ﹤0.01% 7051
2025
Q3 		$10.5K Sell
4,100
-4,300
-51% -$13.6K ﹤0.01% 7139
2025
Q2 		$15.2K Hold
8,400
– – ﹤0.01% 6443
2025
Q1 		$17.1K Buy
8,400
+7,450
+784% +$27.8K ﹤0.01% 5923
2024
Q4 		$5.68K Buy
950
+425
+81% +$3.55K ﹤0.01% 6360
2024
Q3 		$5.12K Sell
525
-450
-46% -$6.05K ﹤0.01% 5870
2024
Q2 		$20K Sell
975
-2,606
-73% -$87.2K ﹤0.01% 5230
2024
Q1 		$162K Sell
3,581
-807
-18% -$38.5K ﹤0.01% 3736
2023
Q4 		$207K Buy
4,388
+3,413
+350% +$190K ﹤0.01% 3832
2023
Q3 		$39.5K Sell
975
-16,775
-95% -$1.7M ﹤0.01% 5321
2023
Q2 		$1.89M Buy
17,750
+17,494
+6,834% +$5.83M 0.01% 1762
2023
Q1 		$76.5K Sell
256
-557
-69% -$238K ﹤0.01% 4526
2022
Q4 		$279K Sell
813
-1,800
-69% -$435K ﹤0.01% 3565
2022
Q3 		$494K Buy
2,613
+1,913
+273% +$444K ﹤0.01% 3246
2022
Q2 		$148K Buy
700
+94
+16% +$19.8K ﹤0.01% 4593
2022
Q1 		$203K Sell
606
-2,725
-82% -$790K ﹤0.01% 4780
2021
Q4 		$1.08M Buy
3,331
+2,806
+534% +$1.2M ﹤0.01% 3278
2021
Q3 		$255K Sell
525
-144
-22% -$63.3K ﹤0.01% 4916
2021
Q2 		$311K Buy
669
+425
+174% +$232K ﹤0.01% 4750
2021
Q1 		$168K Sell
244
-1,575
-87% -$1.27M ﹤0.01% 5198
2020
Q4 		$1.34M Buy
1,819
+188
+12% +$146K ﹤0.01% 2375
2020
Q3 		$1.13M Buy
1,631
+275
+20% +$206K ﹤0.01% 2079
2020
Q2 		$1.15M Buy
1,356
+1,137
+519% +$741K 0.01% 1898
2020
Q1 		$78K Buy
+219
New +$78.7K ﹤0.01% 3459

Other funds holding BTAI

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Group One Trading's BTAI Position: Q1 2026 in Review

Group One Trading reduced its BioXcel Therapeutics (BTAI) stake by 100% in Q1 2026, selling an estimated $5.24K and leaving 1 share worth $1. The position accounts for ﹤0.01% of the portfolio, ranked #7488.

Group One Trading first reported a position in BTAI in Q1 2020 and has held it in 20 quarters since. The position peaked at $1.3M in Q2 2020. 40 funds tracked by Wall St. Rank hold BTAI as of Q1 2026.

  • Group One Trading held 1 share of BioXcel Therapeutics worth $1 as of Q1 2026.
  • Group One Trading sold 3,184 BioXcel Therapeutics shares in Q1 2026, an estimated $5.24K.
  • BioXcel Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #7488 holding.
  • Group One Trading first reported a position in BioXcel Therapeutics in Q1 2020 and has held it in 20 quarters since.
  • Group One Trading's BioXcel Therapeutics position peaked at $1.3M in Q2 2020.
  • 40 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.